Novel Regimens in COVID-19 Treatment

Phase 3

Recruiting

• Conditions: COVID; Corona Virus Infection
• Interventions: Drug: Nitazoxanide

• Registration Number: NCT04382846
• Lead Sponsor: Tanta University

Brief Summary

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

Detailed Description

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019. Some studies demonstrated the efficacy of combined regimen of nitazoxanide and azithromycin or ivermectin and chloroquine.

Study Timeline

• Study First Submitted: 2020-05-07
• Study First Submitted QC: 2020-05-07
• Study Start: 2020-05-08
• Study First Posted: 2020-05-11
• Status Verified: 2020-12
• Last Update Submitted: 2020-12-02
• Last Update Posted: 2020-12-04
• Primary Completion: 2030-12-01
• Study Completion: 2030-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

• Patients with COVID-19 infection

Exclusion Criteria

• Allergy or contraindication to the drugs.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Nitazoxanide	Nitazoxanide	Nitazoxanide with standard protocol of treatment

Primary Outcome Measures

Name	Time	Method
Number of patients with virological cure	6 months	the number of patients with virological cure

Trial Locations

Locations (2)

Tanta University, Assiut University; 🇪🇬 Tanta, Egypt

Sherief Abd-Elsalam; 🇪🇬 Tanta, Egypt